Skip to content
Peptigraph home

Sermorelin Half-Life: How Long It Stays in Your System

How long Sermorelin stays in the body, how that shapes dosing frequency, and what is known about drug testing.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)
Dosing interval
Varies by study
as used in studies
WADA
Prohibited (S2.2.4)
In and out of competition
Detection window
2 findings
from anti-doping studies, below

Sermorelin half-life

Half-life: no published half-life found (PubMed search, 2 Oct 2026). A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray), so we report it per route with the study it came from.

What half-life means

Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.

  • A long half-life lets a drug be dosed less often, for example once a week.
  • A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
  • Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.

What it means for dosing frequency

Dosing intervals used in published studies of Sermorelin:

Changing the interval changes how much drug builds up between doses, so it is not a free choice.

Drug tests and sport

Prohibited by WADA (S2.2.4)

Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.

Detection findings from anti-doping analytical studies:

  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations. · PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples. · PMID 34665524

Tested athletes should treat it as prohibited (s2.2.4) at all times.

Common questions

How long does Sermorelin stay in your system?

We found no published half-life for Sermorelin (PubMed search, 2 Oct 2026). As a rule, most of a dose is cleared after about four to five half-lives.

What is the half-life of Sermorelin?

No published half-life was found in our PubMed search, 2 Oct 2026. We add one with its source and route if a study reports it.

Is Sermorelin on the WADA prohibited list?

Yes. Prohibited by WADA (S2.2.4).

More on Sermorelin

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  5. 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  6. 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  7. 7Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  8. 8PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.